• Greater Twin Cities: 715.294.4371

  • Search

Purchase Femara (Letrozole) 2.5 mg tablets online


How and where to order Letrozole for fertility, for gyno, or to treat breast cancer online:

Shop: MEDS FOR SALE - 5% discount coupon 5OFF
Sellers: LETROZOLE STORES
Prices: from $0.84 per pill
Forms: Letrozole (Femara) 2.5 mg tablets
Quantity: 30-270 pills
Type: Letrozole brand, Femara generic
Payment: Visa, Mastercard, AmEx, Bitcoin
Delivery: Standard airmail and trackable courier service
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Letrozole (Femara) is an aromatase inhibitor indicated for:

  • Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
  • Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
  • First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
  • Off-label uses for gyno, for fertility, stimulation of ovulation.


    Dosage and administration:

    Femara (Letrozole) tablets are taken orally without regard to meals:

  • Recommended dose: 2.5.mg once daily.
  • Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day.


    Overdosage:

    Isolated cases of Femara (Letrozole) tablets overdose have been reported. In these instances, the highest single dose ingested was 62.5 mg or 25 tablets. While no serious adverse reactions were reported in these cases, because of the limited data available, no firm recommendations for treatment can be made. However, emesis could be induced if the patient is alert. In general, supportive care and frequent monitoring of vital signs are also appropriate. In single-dose studies, the highest dose used was 30 mg, which was well tolerated; in multiple-dose trials, the largest dose of 10 mg was well tolerated.

    Lethality was observed in mice and rats following single oral doses that were equal to or greater than 2,000 mg/kg (about 4,000 to 8,000 times the daily maximum recommended human dose on a mg/m2 basis); death was associated with reduced motor activity, ataxia and dyspnea. Lethality was observed in cats following single IV doses that were equal to or greater than 10 mg/kg (about 50 times the daily maximum recommended human dose on a mg/m2 basis); death was preceded by depressed blood pressure and arrhythmias.


    Dosage forms and strengths:

    Femara (Letrozole) 2.5 mg tablets.


    Contraindications:

  • Pregnancy.
  • Known hypersensitivity to the active substance letrozole, or to any of the excipients.


    Warnings and precautions:

  • Decreases in bone mineral density may occur. Consider bone mineral density monitoring.
  • Increases in total cholesterol may occur. Consider cholesterol monitoring.
  • Fatigue, dizziness, and somnolence may occur. Exercise caution when operating machinery.
  • Embryo-fetal toxicity: can cause fetal harm when administered to pregnant women. Obtain a pregnancy test in females of reproductive potential. Advise females of reproductive potential to use effective contraception.


    Adverse reactions, side effects:

    The most common adverse reactions of letrozole (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain, musculoskeletal pain.

    To report suspected side effects of Femara (Letrozole) tablets contact Novartis pharmaceutical company or your local FDA.


    Drug interactions:

  • Tamoxifen: coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels of 38% on average (Study P015). Clinical experience in the second-line breast cancer trials (AR/BC2 and AR/BC3) indicates that the therapeutic effect of Femara therapy is not impaired if Femara is administered immediately after tamoxifen.
  • Cimetidine: a pharmacokinetic interaction study with cimetidine (Study P004) showed no clinically significant effect on letrozole pharmacokinetics.
  • Warfarin: an interaction study (P017) with warfarin showed no clinically significant effect of letrozole on warfarin pharmacokinetics.
  • Other anticancer agents: there is no clinical experience to date on the use of Letrozole (Femara) in combination with other anticancer agents.


    Use in specific populations:

    Lactation: advise not to breastfeed.


    Patient counseling information:

    Embryo-fetal toxicity

    Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during Femara therapy and for at least 3 weeks after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with letrozole tablets.

    Lactation

    Advise women not to breastfeed during Femara (Letrozole) treatment and for at least 3 weeks after the last dose.

    Infertility

    Advise females and males of reproductive potential of the potential for reduced fertility from Femara.

    Fatigue and dizziness

    Since fatigue and dizziness have been observed with the use of Letrozole (Femara) pills and somnolence was uncommonly reported, caution is advised when driving or using machinery.

    Bone effects

    Consideration should be given to monitoring bone mineral density.


  • Preclinical Testing Solutions
    Throughout the
    Product Innovation Cycle.